1Kneller A, Raanani P, Hardan I, et al. Therapy with thalidomide in refractory multiple myeloma patients-the revival of an old drug[J]. Br J Haematol, 2000,108 (2) : 391-393.
8Alexanian R. Management of multiple myeloma. Seminars in hematology,1995,32:20 - 25.
9Myeloma Trialists' Collaborative Group.Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma:an overview of 6,633 patients from 27randomized trials[J].J Clin Oncol,1998,16(12):3832-3842.
10Clerc D,Fermand J P,Mariette X.Treatment of multiple myeloma[J].Joint Bone Spine,2003,70(3):175-186.
3Podar K,Anderson KC.The pathophysiologic role of VEGF in hematologic malignancies therapeutic implications[J].Blood,2005,105(4):1383-1395.
4Zangari M,Anaissie E,Barlogie B,et al.Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy[J].Blood,2001,98(5):1614-1615.
5Zangari M,Barlogie B,Anaissie E,et al.Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy:effects of prophylactic and therapeutic anticoagulation[J].Br J Haematol,2004,126(5):715-721.
6Verheul HM,Jorna AS,Hoekman K,et al.Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets[J].Blood,2000,96(13):4216-4221.
7Palumbo A,Facon T,Sonneveld P,et al.Thalidomide for treatment of multiple myeloma:10 years later[J].Blood,2008,111(8):3968-3977.
8Strukova S.Blood coagulation-dependent inflammation.Coagulation-dependent inflammation and inflammation -dependent thrombosis[J].Front Biosci,2006,11:59-80.
9Auwerda JJ,Sonnevele P,de Maat MP,et al.Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma[J].Haematologica,2007,92(2):279-280.
10Minnema MC,Fijnheer R,de Groot PG,et al.Extremely high levels of von Willebrand factor antigen and of procoagulant factor Ⅷ found in multiple myeloma patients are associated with activity status but not with thalidomide treatment[J].J Thromb Haemost,2003,1(3):445-449.
